ReviewAmerican journal of respiratory and critical care medicine2024
Genetics and Genomics of Pulmonary Fibrosis: Charting the Molecular Landscape and Shaping Precision Medicine.
Open access · greenAbstract readReview
In one paragraph
Review in American journal of respiratory and critical care medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
51citing papers in PubMed, 1 pooled it
19.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 46 citations in OpenAlex.
- Approach to the Evaluation and Management of Interstitial Lung Abnormalities: An Official American Thoracic Society Clinical Statement.American journal of respiratory and critical care medicine · 2025Guideline
- Integrated Bioinformatics and Experimental Validation to Identify Shared Sialylation-Related Signatures in Emphysematous and Fibrotic Lung Disease.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
- Diagnostic, prognostic, and therapeutic challenges in patients with hypersensitivity pneumonitis.ERJ open research · 2026Review
- Multi-omics insights into the mechanisms and prognosis of IPF.Genes and environment : the official journal of the Japanese Environmental Mutagen Society · 2026Review
- A SNP altering the MUC5AC mucin structure is increased in idiopathic pulmonary fibrosis together with the MUC5B SNP.Respiratory research · 2026Article
- Next-Generation Sequencing in Pulmonary Fibrosis: Translational Promise and Current Clinical Limitations.Current issues in molecular biology · 2026Review
- Article
- Geographical, institutional and workplace variability in genetic evaluation, screening practices, multidisciplinary care, and lung transplantation management for familial interstitial lung disease.BMC pulmonary medicine · 2026Article
- The Genetic Landscape of Fibrotic Interstitial Lung Diseases: Clinical Implications and Diagnostic Challenges in Familial Pulmonary Fibrosis.Journal of clinical medicine · 2026Review
- Article
- The clinical and translational perspectives on the lung microbiome in interstitial lung diseases: a bibliometric review.Journal of thoracic disease · 2026Article
- Alveolar niche disruption and aberrant epithelial reprogramming are early hallmarks of idiopathic pulmonary fibrosis.bioRxiv : the preprint server for biology · 2026Article
- Disease Mechanisms and Therapeutic Advances in Idiopathic and Progressive Pulmonary Fibrosis: From Approved Drugs to Emerging Strategies.Journal of clinical medicine · 2026Review
- Nuclear protein 1 is a cell death regulator in primary human airway epithelial cells and reduced in idiopathic pulmonary fibrosis.Scientific reports · 2026Article
- The pleuroparenchymal fibroelastosis atlas reveals aberrant cell states and their zonation as an alternate roadmap to lung fibrosis.Science advances · 2026Article
- Advances in our understanding of distal progenitors in idiopathic pulmonary fibrosis: implications for novel therapeutics.The European respiratory journal · 2026Review
- Human respiratory airway progenitors derived from pluripotent cells generate alveolar epithelial cells and model pulmonary fibrosis.Nature biotechnology · 2026Article
- Clinical and genetic features of idiopathic pulmonary fibrosis in a Korean cohort.Respiratory research · 2026Article
- Familial interstitial lung disease: emerging insights into screening and genetic risk.Frontiers in medicine · 2026Review
- Integrated metabolomic and transcriptomic profiling reveals lipid dysregulation and potential biomarkers in interstitial lung disease.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 17 institutions in 7 countries.
Ayodeji AdegunsoyePulmonary/Critical Care, and.ORCID 0000-0002-7015-9610
Jonathan A KropskiDivision of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0002-8923-1344
Juergen BehrDepartment of Medicine V, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany.ORCID 0000-0002-9151-4829
Timothy S BlackwellDivision of Allergy, Pulmonary, and Critical Care Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.ORCID 0000-0002-0337-7052
Tamera J CorteCentre of Research Excellence in Pulmonary Fibrosis, Camperdown, New South Wales, Australia.ORCID 0000-0002-5076-8929
Vincent CottinNational Reference Center for Rare Pulmonary Diseases (OrphaLung), Louis Pradel Hospital, Hospices Civils de Lyon, ERN-LUNG (European Reference Network on Rare Respiratory Diseases), Lyon, France.ORCID 0000-0002-5591-0955
Allan R GlanvilleLung Transplant Unit, St. Vincent's Hospital Sydney, Sydney, New South Wales, Australia.ORCID 0000-0002-2986-4027
Marilyn K GlassbergDepartment of Medicine, Loyola Chicago Stritch School of Medicine, Chicago, Illinois.ORCID 0000-0003-1990-6614
Matthias GrieseDepartment of Pediatric Pneumology, Dr. von Hauner Children's Hospital, Ludwig-Maximilians-University, German Center for Lung Research, Munich, Germany.ORCID 0000-0003-0113-912X
Gary M HunninghakeHarvard Medical School, Boston, Massachusetts.ORCID 0000-0001-9782-2841
Kerri A JohannsonDepartment of Medicine, University of Calgary, Calgary, Alberta, Canada.ORCID 0000-0003-1205-5511
Michael P KeaneDepartment of Respiratory Medicine, St. Vincent's University Hospital and School of Medicine, University College Dublin, Dublin, Ireland.ORCID 0000-0003-4507-0742
John S KimDepartment of Medicine, School of Medicine, and.ORCID 0000-0002-8887-150X
Martin KolbDepartment of Medicine, McMaster University, Hamilton, Ontario, Canada.ORCID 0000-0003-3837-1467
Toby M MaherDepartment of Medicine, Keck School of Medicine of University of Southern California, Los Angeles, California.ORCID 0000-0001-7192-9149
Justin M OldhamDivision of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Michigan.ORCID 0000-0003-4957-8869
Anna J PodolanczukDepartment of Medicine, Weill Cornell Medical College, New York, New York.ORCID 0000-0002-9559-1485
Ivan O RosasBaylor College of Medicine, Houston, Texas.ORCID 0000-0003-4622-618X
Fernando J MartinezDivision of Pulmonary and Critical Care Medicine, Department of Medicine, Weill Cornell Medicine, New York, New York; and.ORCID 0000-0002-2412-3182
Imre NothDivision of Pulmonary and Critical Care Medicine, University of Virginia, Charlottesville, Virginia.ORCID 0000-0001-9846-5030
David A SchwartzDepartment of Medicine, School of Medicine, University of Colorado, Aurora, Colorado.ORCID 0000-0001-6743-8443
Cornell University · USGerman Center for Lung Research · DEVanderbilt University · USBaylor College of Medicine · USBrigham and Women's Hospital · USLoyola University Chicago · USMcMaster University · CASt Vincent's Hospital Sydney · AUThe University of Sydney · AUUniversité Claude Bernard Lyon 1 · FRUniversity College Dublin · IEUniversity of Calgary · CAUniversity of Chicago · USUniversity of Colorado Anschutz Medical Campus · USUniversity of Michigan · USUniversity of Southern California · USUniversity of Virginia · US
Funding
Mechanisms of Familial Pulmonary FibrosisP01HL092870 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI SCHWARTZ, DAVID ALBERT · 2010 to 2020
$21.6MTargeting early events in MUC5B-driven lung injury and fibrosisP01HL162607 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI David Albert Schwartz · 2023 to 2026
$12.4M1/2 Prospective tReatment EffiCacy in IPF uSlng genOtype for Nac Selection (PRECISIONS) trial and Molecular Endophenotyping in Idiopathic Pulmonary Fibrosis and Interstitial Lung Diseases studyUH3HL145266 · NHLBI · WEILL MEDICAL COLL OF CORNELL UNIV · PI MARTINEZ, FERNANDO J, NOTH, IMRE · 2021 to 2025
$11.6MClinical Genetics and Screening for Pulmonary FibrosisR01HL130974 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI GARY MATTHEW HUNNINGHAKE, Benjamin Alexander Raby · 2016 to 2026
$10.0MGenetic and Genomic Characterization of the Occurrence and Progression of Interstitial Lung AbnormalitiesR01HL135142 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI MICHAEL H. CHO, GARY MATTHEW HUNNINGHAKE · 2017 to 2026
$7.7MInterstitial Lung Abnormalities: Defining the Phenotype, Causes, and Consequences.R01HL111024 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI HUNNINGHAKE, GARY MATTHEW · 2013 to 2022
$6.4MSpatiotemporal genomic regulation of disease initiation and progression in pulmonary fibrosisR01HL145372 · NHLBI · TRANSLATIONAL GENOMICS RESEARCH INST · PI Nicholas Eli Banovich, Jonathan Andrew Kropski · 2019 to 2026
$6.0MPreclinical Pulmonary Fibrosis, an opportune rare disease cohortUH3HL151865 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI SCHWARTZ, DAVID ALBERT · 2022 to 2025
$4.3MMolecular Determinants of Usual Interstitial Pneumonia (UIP)R01HL158668 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI David Albert Schwartz, Ivana V Yang · 2022 to 2026
$3.5MArchitectural structure and regulation of TOLLIP in IPFR01HL130796 · NHLBI · UNIVERSITY OF VIRGINIA · PI NOTH, IMRE · 2016 to 2019
$3.1MGenes and Transcripts that Interact with MUC5B in Pulmonary FibrosisR01HL149836 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI CLOUTHIER, DAVID E., SCHWARTZ, DAVID ALBERT · 2020 to 2023
$3.0MIntegrated analysis of multi-omic QTLs at single cell resolutionR01HG011886 · NHGRI · TRANSLATIONAL GENOMICS RESEARCH INST · PI BANOVICH, NICHOLAS ELI · 2022 to 2025
$2.9MBLRD VA I01 BX002378BLRD VA I01 BX005295BLRD VA I01 BX006121NHGRI NIH HHS R01 HG011886NHLBI NIH HHS K23 HL146942NHLBI NIH HHS K23HL146942NHLBI NIH HHS K23 HL150301NHLBI NIH HHS P01 HL092870NHLBI NIH HHS P01 HL162607NHLBI NIH HHS R01HG011886NHLBI NIH HHS R01 HL111024NHLBI NIH HHS R01 HL130796NHLBI NIH HHS R01 HL130974NHLBI NIH HHS R01 HL135142NHLBI NIH HHS R01 HL145372NHLBI NIH HHS R01HL145372NHLBI NIH HHS R01 HL149836NHLBI NIH HHS R01 HL153246NHLBI NIH HHS R01HL153246NHLBI NIH HHS R01 HL158668NHLBI NIH HHS R01 HL169166NHLBI NIH HHS UH3 HL145266NHLBI NIH HHS UH3 HL151865
Abstract
Recent genetic and genomic advancements have elucidated the complex etiology of idiopathic pulmonary fibrosis (IPF) and other progressive fibrotic interstitial lung diseases (ILDs), emphasizing the contribution of heritable factors. This state-of-the-art review synthesizes evidence on significant genetic contributors to pulmonary fibrosis (PF), including rare genetic variants and common SNPs. The
Indexed as
GenomicsIdiopathic Pulmonary FibrosisMucin-5BPrecision MedicineGenetic Predisposition to DiseaseHumansPolymorphism, Single NucleotidePulmonary FibrosisMUC5B protein, humanMucin-5Bgenetic variantsinterstitial lung diseasesMUC5B promoter variantprecision medicinepulmonary fibrosis
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.